| Literature DB >> 27276018 |
Ana Carolina Sauer Liberato1, Roberta Cunha Matheus Rodrigues2, Thaís Moreira São-João3, Neusa Maria Costa Alexandre2, Maria Cecília Bueno Jayme Gallani4.
Abstract
OBJECTIVE: to psychometrically test the Brazilian version of the Treatment Satisfaction Questionnaire for Medication - TSQM (version 1.4), regarding ceiling and floor effect, practicability, acceptability, reliability and validity.Entities:
Mesh:
Year: 2016 PMID: 27276018 PMCID: PMC4915802 DOI: 10.1590/1518-8345.0745.2705
Source DB: PubMed Journal: Rev Lat Am Enfermagem ISSN: 0104-1169
Sociodemographic characteristics of participants with coronary heart disease (n=190), Campinas, SP, Brazil, 2010-2011
| Sociodemographic Variables | n (%) | Mean (SD*) | Range | Median |
| Gender | ||||
| Male | 120 (63.2) | |||
| Education (years) | 5.4 (4) | 0-20 | 4 | |
| Age (years) | 60.2 (10) | 28-87 | 59.5 | |
| Marital Status | ||||
| With companion | 135 (71.1) | |||
| Race | ||||
| Caucasoid | 135 (71.1) | |||
| Professional Status | ||||
| Active | 59 (31) | |||
| Inactive | 109 (57.3) | |||
| Housewife | 22 (11.6) | |||
| Monthly income (US$)† | ||||
| Family | 921.4 (665.1) | 0-3,447.1 | 734.5 |
*SD = Standard Deviation; †Dollar exchange rate: 1.77 on 07/12/2011.
Clinical characteristics of participants with coronary heart disease (n=190), Campinas, SP, Brazil, 2010-2011
| Clinical Variables | n (%) | Mean (SD*) | Range | Median |
| Acute Coronary Syndrome (ACS - n=189) | ||||
| ST-segment elevation | 112 (58.9) | |||
| Unstable angina | 40 (21.1) | |||
| Non ST-segment elevation | 37 (19.5) | |||
| Years since the last ischemic event | 8.3 (4.9) | 3-27 | 6 | |
| Number of previous MI | 1.4 (1.4) | 0-10 | 1 | |
| Associated conditions | ||||
| Dyslipidemia | 184 (96.8) | |||
| Hypertension | 172 (90.5) | |||
| Diabetes Mellitus | 85 (44.7) | |||
| Number of clinical conditions | 4 (1.7) | 1-15 | 4 | |
| Smoking (current and past) | 125 (65.8) | |||
| Symptoms over the last month | ||||
| Chest pain | 103 (54.2) | |||
| Dyspnea | 93 (48.9) | |||
| Lipothymia | 88 (46.3) | |||
| Number of symptoms over the last month | 2.4 (1.5) | 0-6 | 2 | |
| Treatment of ACS | ||||
| Clinical | 61 (32.1) | |||
| Clinical and chirurgical | 126 (66.3) |
*SD: Standard Deviation; †Left Ventricular Ejection Fraction, ‡LVEF≤58.0%.
Descriptive analyses of medication adherence and satisfaction. Campinas, SP, Brazil, 2010-2011
| Variables | n | % | Mean (SD*) | Range | Median |
| Satisfaction Measure | |||||
| TSQM (version 1.4) | |||||
| Effectiveness | 189 | 67.7 (8) | 27.8-88.9 | 66.7 | |
| Side Effects | 190 | 93.5 (16.9) | 12.5-100 | 100 | |
| Convenience | 190 | 66.3 (9.5) | 33.3-100 | 66.7 | |
| Global satisfaction | 190 | 69.2 (12.6) | 14.3-100 | 71.4 | |
| Adherence Measures | |||||
| Morisky Self-Reported Scale | 190 | 5.8 (2.2) | 4-15 | 5 | |
| Adherence proportion | |||||
| Life-savings drug adherence† | |||||
| Beta-blockers | 143 | 94.4 (16) | 0-100 | 100 | |
| Adherent | 88.8 | ||||
| Antiplatelet | 170 | 92.5 (24.1) | 0-100 | 100 | |
| Adherent | 90.6 | ||||
| Statins | 127 | 95.5 (16.3) | 0-100 | 100 | |
| Adherent | 91.8 | ||||
| Life-savings drugs (associated)‡ | 190 | 94.2 (13) | 0-100 | 100 | |
| Adherent | 87.9 | ||||
| Drugs for symptom relief§ | |||||
| Nitrate | 45 | 88.4 (25.5) | 0-100 | 100 | |
| Adherent | 84.4 | ||||
| Diuretic | 90 | 96.7 (12.4) | 13-100 | 100 | |
| Adherent | 93.3 | ||||
| Digitalis | 7 | 36.1 (47.7) | 0-100 | 0 | |
| Adherent | 28.6 | ||||
| Drugs for symptom relief (associated)§ | 190 | 93.1 (14.1) | 0-100 | 100 | |
| Adherent | 86.3 |
SD: Standard Deviation; †Individuals who presented adherence ≥80% were considered adherent; ‡Drug therapy related to the reduction of morbidity and mortality in coronary heart disease - life-saving therapy - converting enzyme inhibitor (ACEI) or angiotensin receptor antagonists (ARBs), beta-blockers, antiplatelet agents and statins; §Drugs used for symptoms relief in coronary heart disease: digoxin, diuretics and nitrates.
Pearson's correlation coefficients between TSQM (version 1.4) and adherence measures. Campinas, SP, Brazil, 2010-2011
| *r | Adherence† - Symptoms relief | Adherence†- Life-saving | Morisky | TSQM -
| TSQM - | TSQM -
| TSQM - |
| Adherence† - Symptoms relief | 1.0 | ||||||
| Adherence† - Life-saving | 0.82‡ | 1.0 | |||||
| Morisky | -0.24‡ | - 0.26‡ | 1.0 | ||||
| TSQM -
| 0.02 | 0.06 | -0.07 | 1.0 | |||
| TSQM - Side Effects | 0.16§ | 0.04 | -0.18§ | 0.11 | 1.0 | ||
| TSQM -
| -0.03 | 0.05 | -0.09 | 0.19‡ | 0.02 | 1.0 | |
| TSQM - | -0.04 | 0.03 | -0.16‡ | 0.46‡ | -0.02 | 0.15§ | 1.0 |
*r = Pearson's correlation coefficients; †Proportion of adherence; ‡p<0.01; §p≤0.05.